Skip to main content

APOLLOE4

All trials

Alzheimer

APOLLOE4

Leeftijd icoon
50 - 80 years
Diagnose icoon
 Early-stage Alzheimer’s disease and ApoE4/4 genotype
Duratie onderzoek
93 weeks
Locatie icoon
Amsterdam, Den Bosch, and Zwolle

About this research

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). The study drug is taken in the form of a tablet.

ALZ-801 contains an active ingredient called tramiprosate. Tramiprosate disrupts the formation of abnormal forms of a protein called beta-amyloid or Aβ-42. These abnormal amyloid proteins are believed to play an important role in causing cell damage in the brain and in the development of your disease. ALZ-801 interferes with the formation of these abnormal toxic proteins and could possibly slow or stop the worsening of your disease.

You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 9 times, during approximately 93 weeks. In addition, you will also have several telephone conversations. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 6-8 hours, others 3-4 hours. A phone call takes around 15 minutes. The research takes place in Amsterdam, Den Bosch, and Zwolle.

This research is commissioned by Alzheon.

How does the application process go?

You always decide whether you participate in a study. Participation is always voluntary.

  1. You apply via the online form, this is non-binding.
  2. After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
  3. You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
  4. When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
  5. If you decide to participate in the study, you sign a form and will start the study within several weeks.

What are the benefits of Brain Research Center?

  1. You always come first – everything we do revolves around you.
  2. Experienced team of doctors, neuropsychologists, and nurses.
  3. Open and homely atmosphere – this will make you feel relaxed and right at home.
  4. Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
  5. Always nearby – 3 locations spread through the Netherlands.

What's in it for me?

  • You may experience benefits from a new treatment.
  • You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
  • You make a meaningful contribution to a future without Alzheimer’s.
  • You contribute to the advancement of science.

Can I participate?

You can participate when:

  • You have early-stage Alzheimer’s disease and ApoE4/4 genotype
  • You are between 50 and 80 years old.
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.

Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate. 

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle

All trialsAlzheimer

Together

The goal of this study is to evaluate the safety and potential effectiveness of the…

The goal of this study is to evaluate the safety and potential effectiveness of the investigational drug (bepranemab) for participants with MCI or mild Alzheimer’s Disease. The study compares the effect of the active study drug bepranemab with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). Using a placebo will help us identify improvements or side effects which are caused by the active study medication. The study drug is administered through an intravenous (IV) injection.

audience50 - 80 years

levelMild cognitive impairment (MCI) or mild Alzheimer’s disease

duration152 weeks

locationAmsterdam, Den Bosch, and Zwolle